Kuros Biosciences (Formally known as Cytos Biotech; Merged with Kuros Biosurgery)
Wagistrasse 25
Postfach
Zurich-Schlieren
8952
Tel: 41-1-733-47-47
Fax: 41-1-733-47-40
Website: http://www.cytos.com/
Email: info@cytos.com
45 articles about Kuros Biosciences (Formally known as Cytos Biotech; Merged with Kuros Biosurgery)
-
Kuros Reports 163% Growth in Direct MagnetOs Sales and 153% Increase in Total Medical Device Sales for the Full Year 2023
3/13/2024
Kuros Biosciences, a leader in next-generation bone graft technologies, announced financial results for full year 2023 along with continued significant growth.
-
Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update
3/8/2024
Kuros Biosciences, a leader in next-generation bone graft technologies, announced that it will report its full-year financial results and provide a corporate update on its business on March 13, 2024.
-
Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference
2/1/2024
Kuros Biosciences, a leader in next generation bone graft technologies, announced it will present at the CG 2024 Musculoskeletal Conference, to be held in San Francisco on February 12, 2024.
-
Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand
1/31/2024
Kuros Biosciences, a leader in next generation bone graft technologies, announced clearance of a 510 submission from the U.S. Food and Drug Administration related to its MagnetOs ™ Granules.
-
Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA
1/4/2024
Kuros Biosciences announced three advancements related to its MagnetOs portfolio of products: specifically positive results from the MAXA level 1 clinical trial comparing standalone MagnetOs to autograft in a real world patient population in the challenging posterolateral fusion procedure, and two 510 clearances from the U.S. Food and Drug Administration related to its MagnetOs family of products.
-
Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA
12/27/2023
Kuros Biosciences, a leader in next generation bone graft technologies, announced results from two prospective, randomized clinical studies - the STRUCTURE and MAXA trials.
-
Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spinal Cages
11/28/2023
Kuros Biosciences ("Kuros" or the "Company"), a leader in next generation bone graft technologies, announced today that MagnetOs Flex Matrix has been cleared for use in the interbody space by the U.S. Food and Drug Administration (FDA).
-
Kuros Reports a 150% Increase in Direct MagnetOs Sales in the First Nine Months of 2023 and Announces Changes Within the Executive Management
10/12/2023
Kuros Biosciences, a leader in next-generation bone graft technologies, provides an update on its commercial activities for the first nine months of 2023 and announces changes and a transition in responsibilities within the Executive Management.
-
XOMA Acquires Royalty and Milestone Interest in Checkmate’s Vidutolimod (CMP-001) from Kuros Biosciences
7/15/2021
XOMA Corporation, announced it has acquired the royalty interest position Kuros Biosciences holds in Checkmate Pharmaceuticals’ vidutolimod, an advanced-generation Toll-like receptor 9 agonist packaged in a virus-like particle, for $7.0 million upfront plus sales milestones.
-
Clinical Catch-Up: September 2-8
9/9/2019
Last week was a busy week for clinical trial results. Here’s a look at some of the top stories and reporting. -
Kuros Biosciences Signs Agreement with Surgical Specialties on Distribution of MagnetOs in Australia and New Zealand
7/9/2019
Kuros Biosciences announced that its Dutch subsidiary, Kuros Biosciences BV, has signed a distribution agreement for the Australian and New Zealand healthcare markets with Surgical Specialties, a subsidiary of the Paragon Care Group, a leading provider of medical equipment, devices and consumables.
-
Biotech Movers and Shakers Aug. 27
8/27/2018
Who made a splash in the biotech world this week? Here are some notable people. -
Kuros Biosciences Appoints Chief Medical Officer
3/8/2016
-
Kuros Biosurgery Holding Ltd. Closes Merger With Cytos Biotechnology Ltd. Which Is Renamed Kuros Biosciences
1/20/2016
-
LSP’s Portfolio Company Kuros Biosciences Closes Merger With Cytos And Is Now Listed As Kuros Biosciences Ltd On Swiss Stock Exchange
1/19/2016
-
Cytos Biotechnology Ltd. Will Be Renamed Kuros Biosciences , Constitutes Its Board Of Directors And Appoints Executive Officers
1/8/2016
-
VC-Backed Kuros Biosurgery Merges with Cytos Biotech
12/3/2015
-
Cytos Biotechnology AG's Asthma Drug CYT003 Flunks Pivotal Phase 2b Study
4/14/2014
-
Cytos Biotechnology AG Rights Offering Oversubscribed - CHF 24.3 Million Raised
11/18/2013
-
Cytos Biotechnology AG to Host Investor and Analyst R&D Day in New York City
10/17/2013